3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
35
Carcinoma, Hepatocellular
28
Stomach Neoplasms
12
Neoplasm Metastasis
12
Nasopharyngeal Carcinoma
11
Neoplasms
10
Esophageal Neoplasms
10
Melanoma
8
Esophageal Squamous Cell Carcinoma
8
Colorectal Neoplasms
8
Recurrence
7
Lung Neoplasms
7
Breast Neoplasms
7
Biliary Tract Neoplasms
7
Triple Negative Breast Neoplasms
6
Small Cell Lung Carcinoma
5
Rectal Neoplasms
5
Pancreatic Neoplasms
5
Head and Neck Neoplasms
5
Cholangiocarcinoma
5
Squamous Cell Carcinoma of Head and Neck
4
Locally Advanced Rectal Cancer
4
Colonic Neoplasms
4
Carcinoma, Renal Cell
4
Advanced NSCLC
4
Urinary Bladder Neoplasms
3
Sarcoma
3
Liver Neoplasms
3
Leukemia, Myeloid, Acute
3
Hyperthermia
3
Interventions
parathyroid hormone-related peptide (1-36)
2
Musculoskeletal Manipulations
2
Cisplatin
2
niraparib
1
lutetium Lu 177 dotatate
1
copper dotatate CU-64
1
anlotinib
1
adrenosterone
1
Ultrasonography
1
Thalidomide
1
Sunitinib
1
Parathyroid Hormone-Related Protein
1
Parathyroid Hormone
1
Paclitaxel
1
Octreotide
1
Melphalan
1
Lutetium-177
1
Lutetium
1
Irinotecan
1
Immune Checkpoint Inhibitors
1
Hematologic Tests
1
Gemcitabine
1
Filgrastim
1
Etoposide
1
Eating
1
Doxorubicin
1
Diffusion
1
Dexamethasone
1
Dehydroepiandrosterone
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Endocrine System Diseases
×
Immune Checkpoint Inhibitors
×
Clear all
NCT03492242
2019-09-26
CHIMeRA
Groupe Hospitalier Pitie-Salpetriere
Completed
1,000 enrolled